Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Alpha-D-Galactose
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Cerecor
Deal Size : Undisclosed
Deal Type : Collaboration
Details : This trial will study the safety, tolerability, and efficacy of CERC-801 in patients with PGM1-CDG using daily therapeutic doses of CERC-801 in approximately ten patients.
Brand Name : CERC-801
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 17, 2020
Lead Product(s) : Alpha-D-Galactose
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Cerecor
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?